+91 80 2808 2808

Biocon appoints Anupam Jindal as its Chief Financial Officer

  • Posted by: BIOCON

BENGALURU, India September 22, 2020

Biocon Limited (BSE: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced today that Anupam Jindal Chief Financial Officer (CFO). Anupam will head the finance function at Biocon and be part of the Executive Leadership Team. He will repo hief Executive Officer & Managing Director, Siddharth Mittal.

Prior to joining Biocon, Anupam worked with the Vedanta Group of companies for 22 years, where he held the position of Group Chief Financial Officer at Sterlite Technologies Limited since 2006. Anupam played a key role in growing the company’s revenue exponentially through organic capacity expansion and acquisitions, in India and abroad. He was also instrumental in driving several strategic initiatives, such as inception and growth of new business verticals.

Anupam holds a Bachelor of Commerce (B Com) degree from ML Sukhadia University, Udaipur. He is also a Chartered Accountant from the Institute of Chartered Accountants of India and a Company Secretary from the Institute of Company Secretaries of India

Biocon’s Chief Executive Officer and Managing Director, Siddharth Mittal said, “We are pleased to have Anupam join us at this crucial phase of our growth, as we expand our portfolio and enter new geographies, to address patient needs for affordable, high-quality medicines. With his proven track record of steering high-growth companies, Anupam will play a key role in helping deliver on our business goals “

About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>